Home › Pfizer's Ibrance drug slows progression of breast cancer
 

Keywords :   


Pfizer's Ibrance drug slows progression of breast cancer

2015-05-30 19:03:57| Biotech - Topix.net

CHICAGO: A Phase III trial of Pfizer Inc's drug Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer. At the time of an interim analysis, patients given Ibrance in combination with AstraZeneca Plc's Faslodex , a widely used treatment to block estrogen, lived an average of 9.2 months before their cancer worsened.

Tags: drug cancer breast progression

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Ofcom reviews future of DTT in the UK
17.05GTPL offers cable TV directly on Samsung TVs using TVKey
17.05China takes sweeping action to ease property crisis
17.05Warner Bros. Discovery adds 2 million DTC subscribers in 1Q 2024
17.05LOréal Patents Hybrid Mineral and Organic Sunscreen
17.05Telefónica pay TV accesses down 45,000 in 1Q 2024
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
More »